Unexpectedly, the only remaining wild-type KRAS cell line, HROC18, displayed the second-lowest IC50 value for trametinib in the BrdU incorporation assay, while the two CRC lines with oncogenic KRAS mutations, HROC43 and HROC46, were less sensitive. This evidence concerns the gene KRAS and colorectal carcinoma.